Hospital
Henry Mayo Newhall Memorial Hospital
Henry Mayo Newhall Memorial Hospital was paid $17.80M by Medicaid between Jan 2018 and Dec 2024, across 236 billing codes. Its largest line is 0450, Emergency room services — 20% of everything it billed.
33Billing provider infoHENRY MAYO NEWHALL MEMORIAL HOSPITAL
VALENCIA, CA 91355
VALENCIA, CA 91355
33aNPI1780668434assigned 12/05/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.80M
24GClaims830,985
24DCodes billed236
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#132 of 410
Median peer was paid$6.90M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 143,255 | $2.16M | |
| 2019 | 121,446 | $3.21M | |
| 2020 | 86,935 | $1.73M | |
| 2021 | 99,797 | $2.03M | |
| 2022 | 114,669 | $2.57M | |
| 2023 | 141,244 | $3.26M | |
| 2024incomplete | 123,639 | $2.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 20% | 88,862 | 80,146 | $3.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 3,805 | 3,386 | $1.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 5,432 | 5,293 | $1.00M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.1% | 20,095 | 18,745 | $904K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 7,816 | 7,589 | $862K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.9% | 6,107 | 5,035 | $521K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 24,387 | 21,007 | $506K |
| 80053 | Comprehensive metabolic panel | 2.7% | 42,440 | 38,253 | $488K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.7% | 17,683 | 15,593 | $487K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 4,761 | 4,656 | $457K |
| 99199 | Unlisted special service, procedure or report | 2.3% | 9,186 | 8,225 | $408K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 43,690 | 39,199 | $335K |
224 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 5,701 | $334K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.8% | 3,984 | $317K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.7% | 2,202 | $304K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 22,694 | $304K |
| 99284 | Emergency room visit (serious) | 1.7% | 2,790 | $300K |
| 0121 | 1.7% | 224 | $296K | |
| Z7502 | 1.4% | 7,060 | $255K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 1,152 | $179K |
| 84484 | <1% | 17,223 | $170K | |
| 99283 | Emergency room visit (moderate) | <1% | 2,427 | $167K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,224 | $159K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,895 | $142K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,881 | $125K |
| 85610 | <1% | 27,890 | $120K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,172 | $118K |
| 83690 | <1% | 16,982 | $108K | |
| 0270 | <1% | 19,630 | $108K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,757 | $105K |
| 0250 | <1% | 35,814 | $101K | |
| 93971 | <1% | 1,129 | $101K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,758 | $101K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,866 | $99K |
| J3490 | Unclassified drugs | <1% | 24,014 | $92K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,571 | $91K |
| 76830 | Ultrasound, transvaginal | <1% | 1,529 | $84K |
| 83880 | <1% | 3,680 | $83K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,280 | $80K |
| 83735 | <1% | 12,212 | $79K | |
| 84703 | <1% | 12,978 | $78K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,341 | $72K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,062 | $68K |
| 81001 | <1% | 13,617 | $64K | |
| 87631 | <1% | 1,345 | $63K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,666 | $60K |
| 76801 | <1% | 1,416 | $59K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,361 | $59K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,177 | $58K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 586 | $56K |
| 81003 | <1% | 14,185 | $55K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,232 | $55K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,028 | $54K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,789 | $52K |
| 0762 | <1% | 1,187 | $51K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,543 | $50K |
| 70486 | <1% | 401 | $50K | |
| 80305 | <1% | 2,930 | $50K | |
| 87040 | <1% | 4,460 | $47K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,693 | $47K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,679 | $44K |
| 72100 | <1% | 1,645 | $44K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,674 | $43K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,669 | $43K |
| 73562 | <1% | 2,219 | $42K | |
| 73610 | <1% | 1,888 | $42K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 188 | $41K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,841 | $41K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,883 | $40K |
| 87400 | <1% | 5,039 | $37K | |
| 73630 | <1% | 2,000 | $36K | |
| 96376 | <1% | 2,748 | $36K | |
| 85379 | <1% | 3,532 | $35K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,392 | $34K |
| 73030 | <1% | 1,641 | $32K | |
| 80061 | Lipid panel | <1% | 3,019 | $32K |
| 85730 | <1% | 6,158 | $32K | |
| 80329 | <1% | 3,093 | $32K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 749 | $32K |
| 83605 | <1% | 3,081 | $28K | |
| 73130 | <1% | 1,409 | $28K | |
| 80320 | <1% | 1,914 | $27K | |
| 0160 | <1% | 671 | $26K | |
| 87088 | <1% | 4,456 | $26K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,186 | $25K |
| 73110 | <1% | 1,063 | $22K | |
| 90715 | <1% | 786 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,282 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,080 | $21K |
| 84702 | <1% | 1,804 | $20K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 674 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,141 | $18K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 674 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,470 | $17K |
| 82947 | <1% | 6,101 | $17K | |
| 87081 | <1% | 1,745 | $17K | |
| 82150 | <1% | 3,066 | $16K | |
| 87186 | <1% | 2,084 | $15K | |
| 82077 | <1% | 1,036 | $13K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,379 | $13K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,863 | $13K |
| 72040 | <1% | 548 | $13K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,259 | $13K |
| 80299 | <1% | 1,146 | $13K | |
| 70496 | <1% | 57 | $13K | |
| 76642 | <1% | 334 | $13K | |
| 59025 | Fetal non-stress test | <1% | 966 | $12K |
| 87807 | <1% | 1,001 | $12K | |
| 70498 | <1% | 58 | $12K | |
| 74018 | <1% | 619 | $12K | |
| 0761 | <1% | 295 | $11K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,331 | $10K |
| 86901 | <1% | 3,371 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,305 | $10K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,145 | $9K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 858 | $9K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 51 | $9K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 237 | $9K |
| 86900 | <1% | 3,353 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,050 | $8K |
| 87077 | <1% | 1,317 | $8K | |
| 73080 | <1% | 337 | $8K | |
| Z7610 | <1% | 641 | $7K | |
| 85027 | <1% | 1,356 | $7K | |
| 73590 | <1% | 322 | $7K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 828 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 52 | $7K |
| 99070 | <1% | 1,779 | $7K | |
| 80143 | <1% | 551 | $7K | |
| 29125 | <1% | 271 | $7K | |
| A4649 | Surgical supply; miscellaneous | <1% | 911 | $7K |
| 93970 | <1% | 40 | $6K | |
| 96367 | <1% | 215 | $6K | |
| 73502 | <1% | 217 | $5K | |
| 84145 | <1% | 158 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 694 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 337 | $5K |
| 84100 | <1% | 1,224 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 15 | $5K |
| 76641 | <1% | 98 | $4K | |
| 86850 | <1% | 898 | $4K | |
| 80047 | <1% | 267 | $4K | |
| 0710 | <1% | 907 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 346 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 898 | $4K |
| 73090 | <1% | 156 | $3K | |
| 90714 | <1% | 143 | $3K | |
| 82550 | <1% | 564 | $3K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 372 | $3K |
| 12001 | <1% | 38 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,064 | $3K |
| 81025 | <1% | 677 | $3K | |
| 73140 | <1% | 210 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 549 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 40 | $2K |
| 0301 | <1% | 454 | $2K | |
| 84439 | <1% | 213 | $2K | |
| 0324 | <1% | 350 | $2K | |
| 84436 | <1% | 351 | $2K | |
| 93017 | <1% | 30 | $2K | |
| 0370 | <1% | 54 | $2K | |
| 29515 | <1% | 47 | $1K | |
| 86140 | <1% | 327 | $1K | |
| 99000 | <1% | 363 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 72 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 389 | $1K |
| 76870 | <1% | 27 | $1K | |
| 87147 | <1% | 224 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 369 | $1K |
| 0637 | <1% | 667 | $990.34 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $958.61 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 102 | $950.17 |
| 86308 | <1% | 62 | $935.99 | |
| 0403 | <1% | 60 | $859.05 | |
| 97161 | <1% | 40 | $846.52 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 578 | $834.77 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,588 | $808.17 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 496 | $799.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 16 | $748.17 |
| 10060 | <1% | 59 | $739.20 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,015 | $729.82 |
| 12002 | <1% | 58 | $686.02 | |
| 82805 | <1% | 30 | $676.94 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 29 | $614.49 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 13 | $609.56 |
| 87070 | <1% | 90 | $594.19 | |
| 0420 | <1% | 75 | $590.01 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 98 | $553.13 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 503 | $511.06 |
| G0378 | Hospital observation service, per hour | <1% | 17 | $472.89 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 52 | $468.26 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 32 | $428.69 |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 22 | $415.04 |
| 0258 | <1% | 407 | $408.04 | |
| 0360 | <1% | 74 | $394.24 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 660 | $350.78 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 84 | $326.11 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 68 | $296.10 |
| 12011 | <1% | 12 | $288.81 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 154 | $246.78 |
| 94644 | <1% | 14 | $217.66 | |
| 85652 | <1% | 126 | $201.62 | |
| 80076 | <1% | 47 | $187.59 | |
| 73060 | <1% | 14 | $184.62 | |
| 82010 | <1% | 30 | $166.98 | |
| 73552 | <1% | 14 | $155.32 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 81 | $139.73 |
| 87210 | <1% | 54 | $138.42 | |
| 87205 | <1% | 26 | $78.16 | |
| J7612 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | <1% | 46 | $76.46 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 33 | $71.41 |
| 0636 | <1% | 320 | $62.56 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 12 | $62.26 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 119 | $62.06 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $61.84 |
| 97016 | <1% | 53 | $55.16 | |
| 0260 | <1% | 18 | $49.60 | |
| 99072 | <1% | 27 | $39.54 | |
| 29130 | <1% | 12 | $36.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 16 | $24.68 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 73 | $18.40 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 14 | $10.08 |
| 0305 | <1% | 381 | $4.97 | |
| 0302 | <1% | 57 | $4.09 | |
| 0307 | 0% | 129 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 1,469 | $0.00 |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 42 | $0.00 |
| 0352 | 0% | 13 | $0.00 | |
| 0306 | 0% | 62 | $0.00 | |
| 93042 | 0% | 33 | $0.00 | |
| 0300 | 0% | 489 | $0.00 | |
| 0730 | 0% | 105 | $0.00 | |
| 0940 | 0% | 55 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 99499 | 0% | 18 | $0.00 | |
| 0760 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSEAVER, ROGER (PRESIDENT AND C.E.O.)